21 results about "Leishmania" patented technology

The invention relates to the technical field of antibody detection, and discloses a canine entomophilous disease quintuplet antibody detection card, a preparation method thereof and a kit. The detection card comprises the following five detection antigens a)-e): a) a leishmania antigen which is fusion protein of rk39, rk26 and rk9; b) a babesia antigen which is a fusion protein of TRAP and rBcMSA1 / rBcSA1; c) an amorphous antigen which is a fusion protein of P44 and OMP-1X; the detection card and the kit have the advantages that joint detection of IgG (immunoglobulin G) and IgM (immunoglobulin M) antibodies corresponding to canine Ehrlichia, canine anaplasmosis, canine babesiosis, canine lyme disease and canine leishmania can be realized by the detection card and the kit, and the detection sensitivity and the specificity are high. The detection card and the kit can be used for detecting canine Ehrlichia, canine anaplasmosis, canine babesiosis, canine lyme disease and canine leishmania. The detection card and the kit have the advantages that the detection card and the kit can be used for detecting canine Ehrlichia, canine anaplasmosis, canine babesiosis and canine leishmania;

The invention discloses a recombinant protein for detecting leishmania as well as a coding gene, a preparation method and application of the recombinant protein, an amino acid sequence of the recombinant protein is formed by fusing a K39 protein partial sequence, a K26 protein partial sequence and a K9 protein complete sequence, and the amino acid sequence of the recombinant protein is as shown in SEQ ID NO.1. The recombinant protein used in the invention is fused with a partial sequence of a K39 protein, a partial sequence of a K26 protein and a complete sequence of a K9 protein; the recombinant protein is combined with a double-antigen sandwich enzyme-linked immunosorbent assay and an optical excitation chemiluminescence technology, a clinical detection technology which is high in sensitivity, short in time consumption and simple and convenient to operate is established, and the technical problem that high sensitivity and high detection efficiency of commercialized products for detecting the canine leishmanian antibody cannot be considered at the same time at present is solved.

The present invention relates to the use of parasites and extracellular vesicles obtained from parasites for cancer treatment. The aim of the present invention is to use parasites and extracellular vesicles obtained from parasites in cancer treatment and to load active substances onto the exosomes by using the drug loading capacity of the exosomes and thus to carry the specific drug directly to the target cancer cells without causing any side effects on healthy cells and thereby to increase the bioavailability of the drug to achieve the desired effect in the tumor-specific target area. Within the scope of the present invention, in particular, the infantile leishmania parasite is used as a source of extracellular vesicles.

The present application relates to glycoengineered bifunctional degradation derivatives, populations of glycoengineered bifunctional degradation derivatives, Leishmania host cells for producing the glycoengineered bifunctional degradation derivatives, methods for genetically engineering the Leishmania host cells, methods for culturing the Leishmania host cells, methods for making glycoengineered bifunctional degradation derivatives using the Leishmania host cells, and methods of using the glycoengineered bifunctional degradation derivatives. In particular, the glycoengineered bifunctional degradation derivatives comprise biantennary GalNAc-terminated N-glycans, specifically A2GalNAc2.

The present invention relates to quinone-derived compounds with leishmanicidal activity and to the use of same in the pharmaceutical industry, specifically in the field of parasitic diseases. The invention relates specifically to a compound of formula (I), the isomeric forms thereof and the salts of same, wherein R1 and R3 are hydrogen and R2 is selected from the list consisting of cyclopentyl, cycloheptyl, 3-methyl-pentyl and adamantane, or wherein R1 and R2 are hydrogen and R3 is selected from the list consisting of cyclopentyl, cyclohexyl and cycloheptyl.

The present invention provides a primer for detecting Leishmania infantum infection in infants and its application, belonging to the field of biotechnology. The present invention can diagnose VL-HLH sensitively and accurately, and the obtained amplification product can be used for sequencing. According to the sequencing results, comparison in the NCBI database, phylogenetic tree analysis and identification can be carried out, so as to quickly diagnose and identify the species of Leishmania, which has great guiding significance for the treatment and prognosis of this disease. The present invention uses qPCR to amplify and quantify kDNA, and can further obtain the load of Leishmania in the sample, which has great reference value for clinical treatment and prognosis, and is more conducive to the popularization and application of using PCR to diagnose VL-HLH.

The present invention relates to a cationic or neutral gold(I) complex with fluorinated ligands of the NHC type as well as its uses as an anti-oxidant, anti-cancer, anti-bacterial and / or anti-parasitic agent and in particular an anti-leishmanial agent.

The presently disclosed subject matter provides a method and pharmaceutical composition for long-term use in treating or preventing disease conditions caused by Leishmania species parasites such as Leishmaniasis. The pharmaceutical composition is a long-term injectable composition that can include a dose of Itraconazole and a dose of Amiodarone in an amount effective to treat Leishmaniasis, or in an amount effective to prevent Leishmaniasis in a human or animal patient such as a mammal. The pharmaceutical composition may also include a pharmaceutically acceptable vehicle, carrier, or excipient. The long-term method for treating or preventing Leishmania disease is carried out by a single injection of Itraconazole and Amiodarone in an amount effective to treat a subject in need thereof, and / or in an amount effective to prevent the subject from contracting the disease so that repeated dosages are not required again for a long-term period such as 6 or 12 months. The present compositions, methods, and uses are safer and longer lasting, more patient friendly, and provide a safer and more effective way of treating or preventing Leishmaniasis than previously possible.

The present invention relates to the fields of veterinary medicine and virology and provides a vaccine against leishmaniasis. In particular, the invention relates to an isolated polynucleotide comprising (i) a first expression cassette comprising a nucleic acid encoding heat shock protein (hsp) 65, and (ii) a second expression cassette comprising a nucleic acid encoding LACK (Leishmania homologue of receptors for activated C kinase). In other embodiments, the invention relates to a DNA plasmid comprising the polynucleotide, a DNA vaccine for use in the treatment of leishmaniasis, and a method of immunizing a subject against an infection with leishmaniasis.

The embodiment of the invention provides a new application of glibenclamide or pharmaceutically acceptable salt thereof and / or flufenamic acid or pharmaceutically acceptable salt thereof, which can improve the leishmania killing capability of macrophages in a host of leishmania, can be used in drugs for preventing and / or treating leishmania, and can be used for preparing medicines for preventing and / or treating leishmania. And the probability that the host infects leishmania is reduced.

This disclosure describes compounds of Formula I and Formula II, pharmaceutically acceptable salts or derivatives thereof, and pharmaceutical compositions thereof, useful in treating infections caused by parasitic protozoa, in particular protozoa of the genera Leishmania or Trypanosoma.

The application belongs to the technical field of organic synthesis chemistry, and particularly relates to an azido tellurium ether derivative and a preparation method and application thereof. In an organic solvent, an olefin, ditelluride and azidotrimethylsilane are used as raw materials, and a stirring reaction is carried out under the presence of a photocatalyst and under the condition of visible light irradiation to obtain the azido tellurium ether derivative. The method has mild reaction conditions, simple operation, high yield and good functional group compatibility, and conforms to the principle of green chemistry. Meanwhile, the azido tellurium ether derivative provided by the application has good inhibitory activity on Leishmania, which provides a drug lead compound for the development of a new type of antiparasitic drug, and has important significance for the prevention and / or treatment of Leishmaniasis.

Inhibitors directed at enzymes of the pentose phosphate pathway of protozoan parasites, e.g., Trypanosoma cruzi glucokinase, are described. Inhibitors are derivatives of gossypol (2,2′-Bis(formyl-1,6,7-trihydroxy-5-isopropyl-3-methylnaphthalene). The inhibitors can specifically target glucokinase and hexokinase of Trypanosoma cruzi (T. cruzi), Trypanosoma brucei (T. brucei), and Leishmania spp. and are useful in treatment of parasitic diseases including Chagas' disease and African sleeping sickness, among others.

The invention provides a primer for detecting leishmania infection of infants and an application of the primer, and belongs to the technical field of biology. According to the invention, VL-HLH can be sensitively and accurately diagnosed, the obtained amplification product can be used for sequencing, comparison in an NCBI database and phylogenetic tree analysis and identification according to the sequencing result, the variety of leishmania can be rapidly diagnosed and identified, and great guiding significance is provided for treatment and prognosis of the leishmania. According to the present invention, the qPCR is adopted to amplify and quantify the kDNA, such that the load of the leishmania in the sample can be further obtained, the large reference value is provided for clinical treatment and prognosis, and the popularization and the application of the PCR diagnosis of the VL-HLH are easily achieved.

The present invention relates to the technical field of antibody detection, and discloses a canine vector-borne disease five-in-one antibody detection card and a preparation method and a kit thereof. The detection card includes the following a) to e) five detection antigens: a) Leishmania antigen: a fusion protein of rk39, rk26 and rk9; b) Babesia antigen: a fusion protein of TRAP and rBcMSA1 / rBcSA1; c) Anaplasma antigen: a fusion protein of P44 and OMP‑1X; d) Ehrlichia antigen: a gp19 protein; e) Lyme antigen: an outer membrane protein of Borrelia burgdorferi OspC. The detection card and kit of the present invention can realize the combined detection of IgG and IgM antibodies corresponding to canine ehrlichiosis, canine anaplasmosis, canine babesiosis, canine Lyme disease and canine leishmaniasis, and have high detection sensitivity and specificity.

Disclosed herein are methods of detecting microbial infection in mammalian subjects comprising treatment of a sample and detection of galactofuranose (galF)-containing antigenic components utilizing monoclonal antibodies. The methods disclosed provide for pretreatment of biological samples, such as urine samples, to maximize detection of galF antigens and improvement of sensitivity of galF antigen detection assays. The methods include minimizing intelectin-1 binding to galF antigens and improvement of monoclonal antibody binding. The detection methods are useful for identifying the presence of microbial antigens related to bacterial, fungal, and parasitic pathogens, including Streptococcus pneumoniae, Aspergillus species, Fusarium species, Coccidioides species, Cryptococcus species, Histoplasma species, and Leishmania species.

The present invention relates to quinone-derived compounds with leishmanicidal activity and to the use of same in the pharmaceutical industry, specifically in the field of parasitic diseases. The invention relates specifically to a compound of formula (I), the isomeric forms thereof and the salts of same, wherein R1 and R3 are hydrogen and R2 is selected from the list consisting of cyclopentyl, cycloheptyl, 3-methyl-pentyl and adamantane, or wherein R1 and R2 are hydrogen and R3 is selected from the list consisting of cyclopentyl, cyclohexyl and cycloheptyl.

The present invention relates to compounds of formula (I), in addition to the use thereof for the treatment and / or prevention of diseases caused by protozoa, especially those belonging to the genus Leishmania or Trypanosoma. The present invention likewise relates to pharmaceutical compositions comprising said compounds.

The invention belongs to the field of molecular biology detection, particularly relates to detection of leishmania and co-infection pathogens thereof, and more particularly relates to detection and distinguishing of at least four pathogens in leishmania, HIV, plasmodium, schistosome, leprosy bacillus and mycobacterium tuberculosis. According to the combined detection composition provided by the invention, different pathogens are detected by mainly utilizing a multiple fluorescent PCR analysis method and detecting target spots on the different pathogens, so that detection and distinguishing of at least four pathogens in leishmania, HIV, plasmodium, schistosome, leprosy bacillus and mycobacterium tuberculosis are simultaneously realized in a single-tube reaction system; the detection efficiency is improved. The composition disclosed by the invention is high in detection sensitivity which reaches 400 copies / mL, and also has good specificity.

The invention relates to a method for detecting antibodies against Leishmania in a biological sample. The invention further relates to a test for carrying out the method, the production of the test antigen, and the test antigen with SEQ ID NO. 8.

The present invention relates to chimeric proteins, their uses and production method comprising native protein fractions from Leishmania infantum for the Visceral Leishmaniasis diagnosis. The invention also relates to nucleic acid, expression cassette, expression vector, host cell, visceral leishmaniasis diagnostic kit, visceral leishmaniasis diagnostic kit, visceral leishmaniasis diagnostic method, and vaccine composition.